醋甲唑胺(Methazolamide) - 药物靶点：CAs_在研适应症：青光眼_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Methazolamide (JAN/USP/INN)、Methenamide、Neptazaneat

+ [6]

靶点

CAs

作用机制

CAs抑制剂(碳酸酐酶家族抑制剂)

治疗领域

眼部疾病

在研适应症

青光眼

非在研适应症-

原研机构

Lederle Laboratories

在研机构-

非在研机构

Lederle Laboratories

最高研发阶段批准上市

首次获批日期

美国 (1959-01-26),

青光眼

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C5H8N4O3S2

InChIKeyFLOSMHQXBMRNHR-UHFFFAOYSA-N

CAS号554-57-4

关联

14

项与醋甲唑胺相关的临床试验

ChiCTR2400089203 / Suspended临床4期IIT

Comparative Study on the Clinical Efficacy of Methazolamide and Acetazolamide in the Prevention of Acute Mountain Sickness

开始日期2024-09-08

申办/合作机构-

NCT05575180 / Completed临床4期IIT

Effect of Acetazolamide and Methazolamide on Hypoxic Exercise Performance

A single-centered randomized doubled blinded placebo-controlled cross-over trial comparing two the effect of two carbonic anhydrase inhibitors on exercise performance in acute hypoxia. Participants will be young (under 40 years of age), healthy males and females who are regularly physically active.

开始日期2023-08-11

申办/合作机构

The University of Waterloo

[+1]

NCT05498103 / Active, not recruiting临床4期IIT

Use of Methazolamide to Lower Intraocular Pressure

The purpose of this study is to evaluate the effect of methazolamide, 25 mg or 50 mg tablets once a day for a week than twice a day for a week, on lowering intraocular pressure and the safety of methazolamide.

开始日期2023-02-17

申办/合作机构

University of Colorado Denver

100 项与醋甲唑胺相关的临床结果

登录后查看更多信息

100 项与醋甲唑胺相关的转化医学

登录后查看更多信息

100 项与醋甲唑胺相关的专利（医药）

登录后查看更多信息

416

项与醋甲唑胺相关的文献（医药）

2024-11-01·Ophthalmology

Nationwide prevalence and geographic variation of idiopathic intracranial hypertension among women in the United States

Article

作者: Ahmad, Baseer ; Amin, Sejal ; Liu, Grant T. ; Kim, B. Michelle ; Stein, Joshua ; Pershing, Suzann ; Munir, Saleha ; Shrivastava, Anurag ; Feldman, Robert ; Fraz, Muhammad A. ; Woreta, Fasika ; DeLott, Lindsey ; Sarrapour, Soshian ; Bryar, Paul ; Nwanyanwu, Kristen ; Vanderbeek, Brian L. ; McMillian, Brian ; Lum, Flora ; Munir, Wuqaas ; Stagg, Brian C. ; Ramachandran, Rajeev ; Chen, Jinbo ; Patnaik, Jenna ; French, Dustin ; Sun, Catherine ; Lynch, Anne M. ; Sheybani, Arsham ; Deiner, Michael ; Wang, Sophia Y. ; Chen, John J. ; Schultz, Jeffrey S. ; Srikumaran, Divya ; Hamedani, Ali G. ; Edwards, Paul A. ; Wirostko, Barbara

OBJECTIVEThe prevalence of idiopathic intracranial hypertension (IIH) is increasing, but this has not been examined on a nationwide scale. Our objective was to determine the nationwide prevalence and geographic distribution of IIH among women in the U.S.DESIGNRetrospective cross-sectional study using Medicaid claims and electronic health record data from the IRIS® Registry (Intelligent Research in Sight) and Sight Outcomes Research Collaborative (SOURCE).PARTICIPANTSFemale Medicaid beneficiaries aged 18-55 with IIH diagnoses and prescriptions for acetazolamide or methazolamide in 2018, excluding those with other causes of intracranial hypertension. We also calculated the proportion of female IIH patients in the U.S. who were insured by Medicaid by combining analyses from the IRIS® Registry and SOURCE.METHODSTo calculate the total number of IIH patients in the U.S. and by state, we divided the number of Medicaid beneficiaries with IIH by the proportion of IIH patients insured by Medicaid. We then used census data from the 2018 American Community Survey to calculate prevalence.MAIN OUTCOME MEASURESWe compared the geographic distribution of IIH to obesity prevalence data from the 2018 Behavioral Risk Factor Surveillance System, using the Moran's I statistic to test for spatial variation. In a validation study, we compared the calculated prevalence of IIH in Minnesota to similar data from the Rochester Epidemiology Project.RESULTSOf 13,959 female Medicaid beneficiaries with IIH, 6,828 had a prescription for acetazolamide or methazolamide. In the IRIS® Registry and SOURCE, 25% of IIH patients were insured by Medicaid (95 % CI: 16-33%), suggesting that there were 27,312 women aged 18-55 with IIH taking acetazolamide or methazolamide in 2018 (6,828 / 0.25 = 27,312). Prevalence was 3.44 per 10,000 (95% CI: 2.61-5.39), and there was significant geographic variation (Moran's I statistic 0.20, P = 0.03) with higher prevalence in states where obesity was more common. The calculated prevalence of IIH in Minnesota was statistically equivalent to Rochester Epidemiology Project data (P < 0.05 for equivalence test).CONCLUSIONSIIH affects 3.44 per 10,000 women aged 18-55 in the U.S., and there is significant geographic variation, some of which is explained by variation in obesity prevalence.

2024-08-01·Translational Andrology and Urology

External pressure induces the dysfunction of spermatogonia via triggering the intrinsic pathway of apoptosis

Article

作者: Long, Houtao ; Liu, Yuxin ; Zhang, Haiyang ; Zhao, Yong ; Zhang, Daofeng ; Zheng, Junhao ; Sun, Qihao ; Du, Kun

BackgroundCryptorchidism, the failure of testes to descend into the scrotum, exposes the testes to higher temperature and external pressure. Scholars from Razi University found through research conducted at different pressure gradients (0, 25, 50, and 100 mmHg) and time gradients (2 and 4 h) that high hydrostatic pressure may lead to sperm apoptosis. In this work, we investigated the effect of external pressure on spermatogonia, exploring a new mechanism of male infertility caused by cryptorchidism.MethodsVarious pressure gradients (0, 25, 50, and 100 mmHg) were applied to spermatogonia for different durations (0, 2, and 4 h) in the Cell Counting Kit-8 (CCK8) experiment. Morphological changes, cell ultrastructure, apoptosis rates, and the expression of apoptosis-related proteins (bax, bcl-2, caspase-3, and caspase-9) were assessed through immunofluorescence, electron microscopy, terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) assay, flow cytometry, immunohistochemistry, real-time quantitative polymerase chain reaction (qPCR), and western blot.ResultsThe cell viability assay showed that higher external pressure had a greater negative time-dependent impact on cell viability. Immunofluorescence results indicated that external pressure stimuli altered the morphology of spermatogonia. The results of TUNEL assay and flow cytometry demonstrated that external pressure stimuli induced apoptosis in spermatogonia. Transmission electron microscopy (TEM) observations showed the generation of apoptotic bodies, mitochondrial swelling, vacuolization, and mitochondrial cristae fusion. The results of immunohistochemistry indicated that pressure induced the expression of caspase-3 and caspase-9 proteins. qPCR and western blot analyses revealed an increased ratio of bax/bcl-2 and expression of caspase-3 and caspase-9. Methazolamide (cytochrome C inhibitor) blocked the pressure-induced cell apoptosis and inhibited the activation of caspase-3 while Z-IETD-FMK (caspase-8 inhibitor) did not.ConclusionsExternal pressure promotes spermatogonia apoptosis through the intrinsic apoptosis pathway, which may be one of the mechanisms of male infertility induced by cryptorchidism.

2024-07-01·Journal of Voice3区 · 医学

Treatment of Essential Vocal Tremor: A Scoping Review of Evidence-Based Therapeutic Modalities

3区 · 医学

Review

作者: Khoury, Sami ; Randall, Derrick R

OBJECTIVES/HYPOTHESISEssential vocal tremor (EVT) is an uncommon but challenging condition to manage. Several medical and interventional treatment options have been reported but efficacy remains unclear. We performed a scoping review of high-quality clinical trials to identify effective evidence-based treatments for EVT.STUDY DESIGNScoping review.METHODSRelevant studies were identified using the databases MedLine, Cochrane Central Register of Controlled Trials, and Embase. Subjective and objective outcomes for each modality were analyzed and the effect sizes were quantified using Hedges' g measure to allow comparison between studies.RESULTSWe identified 421 studies eligible for screening with 11 included in the final analysis. Evidence supporting effective EVT treatments was found for bilateral versus unilateral deep brain stimulation (DBS) (Hedges' g 0.65, 95% CI = 0.10-1.20) and octanoic acid (Hedges' g 1.15, 95% CI = 0.40-1.90). Evidence to support the use of methazolamide was not sufficient (Hedges' g 0.51, 95% CI = -0.64 to 1.66). Botulinum toxin (BT) injections were equivalent when comparing unilateral versus bilateral (Hedges' g -0.18, 95% CI = -1.06 to 0.70); BT did not display any advantage over propranolol (Hedges' g -0.47, 95% CI = -1.73 to 0.78) or injection augmentation (Hedges' g 0.068, 95% CI = -0.98 to 1.12).CONCLUSIONSOur review finds very little high-quality evidence supporting any treatment for EVT. Octanoic acid reduced fluctuations in EVT but did not affect the perception of the tremor. In refractory cases, bilateral DBS was superior to unilateral DBS in improving subjective voice outcomes. Unilateral and bilateral BT injections were equivalent, and BT injection was not more effective than injection augmentation. Further direct comparison in well-designed prospective studies may help clarify optimal treatment for EVT patients.

100 项与醋甲唑胺相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00655	醋甲唑胺	S01EC05	DB00703

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
青光眼	美国	-	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02463357 (CTgov)	临床4期	高原反应	148	Quercetin (Quercetin)	壓遞顧願簾醖餘顧醖廠(積繭觸積壓積鹹構簾醖) = 醖憲繭顧遞範淵製醖鏇構夢選醖襯餘範築鏇繭 (廠網鹽繭蓋鏇蓋簾窪醖, 淵簾製鹹鏇憲觸蓋選壓 ~ 蓋醖範鏇壓鹹繭獵簾醖) 更多	-	2021-03-30
				Methazolamide+Nifedipine extended release (Nifedipine+Methazolamide)	壓遞顧願簾醖餘顧醖廠(積繭觸積壓積鹹構簾醖) = 憲鹹鑰獵鹹鏇蓋簾網衊構夢選醖襯餘範築鏇繭 (廠網鹽繭蓋鏇蓋簾窪醖, 遞願獵築衊鑰夢鏇鑰製 ~ 艱構鏇遞艱願製獵鹹壓) 更多
Abstract 2013 (AACR2019)	N/A	胰腺腺泡癌	-	Methazolamide + Gemcitabine	憲壓構艱鬱觸繭醖願範(鹹顧鹹獵遞膚築構獵鹹) = anti-angiogenic potential viz. would healing, tube formation and expression of important anti-angiogenic markers like HIF1α, VEGF were profoundly modulated in MZM and combination group 觸淵網鏇淵選膚窪簾廠 (糧鹹構夢鹽網鑰觸構憲 ) 更多	积极	2019-07-01
				Methazolamide
NCT02758470 (Pubmed \| FASEB J)	临床4期	缺氧	13	Acetazolamide	選範淵築鑰醖餘夢鹽願(獵鹹膚鏇鬱願鑰遞憲艱) = 獵鏇顧網糧顧積繭齋觸壓築簾繭遞繭鬱鬱積膚 (糧鏇襯積繭壓蓋餘選蓋 ) 更多	-	2018-09-01
				Methazolamide	選範淵築鑰醖餘夢鹽願(獵鹹膚鏇鬱願鑰遞憲艱) = 憲壓襯衊鏇觸齋簾壓獵壓築簾繭遞繭鬱鬱積膚 (糧鏇襯積繭壓蓋餘選蓋 ) 更多
NCT01587027 (CTgov)	临床1期	高原反应	16	Methazolamide+Aminophylline (Sequence A)	糧鹹積糧襯艱範鹽簾構(鏇鑰鹹膚獵淵衊餘餘網) = 製觸廠廠夢餘顧糧觸網鹹築衊鹹鬱餘獵壓壓鑰 (繭膚鑰衊廠繭製鹹製製, 壓廠願選簾齋鑰壓壓窪 ~ 願觸鏇齋艱糧範糧餘鹹)	-	2014-06-09
				Methazolamide+Aminophylline (Sequence B)	糧鹹積糧襯艱範鹽簾構(鏇鑰鹹膚獵淵衊餘餘網) = 蓋餘衊膚窪遞憲齋願範鹹築衊鹹鬱餘獵壓壓鑰 (繭膚鑰衊廠繭製鹹製製, 積繭膚遞構蓋鏇簾糧艱 ~ 壓廠遞膚鏇築鏇夢餘窪)
AAO2002	N/A	Stevens-Johnson综合征	-	Methazolamide	(糧齋範夢憲觸簾鏇衊衊) = 製鬱範衊糧遞窪廠衊網構艱鹽餘願範積糧簾製 (齋憲夢鑰壓簾繭遞醖築 ) 更多	-	2002-10-22